BRPI0519865A2 - serina recombinases sìtio-especìficas e métodos para seu uso - Google Patents

serina recombinases sìtio-especìficas e métodos para seu uso

Info

Publication number
BRPI0519865A2
BRPI0519865A2 BRPI0519865-8A BRPI0519865A BRPI0519865A2 BR PI0519865 A2 BRPI0519865 A2 BR PI0519865A2 BR PI0519865 A BRPI0519865 A BR PI0519865A BR PI0519865 A2 BRPI0519865 A2 BR PI0519865A2
Authority
BR
Brazil
Prior art keywords
recombination
binding site
site
recombinase
attp
Prior art date
Application number
BRPI0519865-8A
Other languages
English (en)
Inventor
Malla Padidam
Original Assignee
Intrexon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Corp filed Critical Intrexon Corp
Publication of BRPI0519865A2 publication Critical patent/BRPI0519865A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/22—Endodeoxyribonucleases producing 3'-phosphomonoesters (3.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)

Abstract

SERINA RECOMBINASES SìTIO-ESPECìFICAS E MéTODOS PARA SEU USO. A presente invenção refere-se a um método para obter a recombinação sítio-específica em uma célula eucariótica, o método compreendendo o fornecimento de uma célula eucariótica que compreende um primeiro sítio de ligação de recombinação e um segundo sítio de ligação de recombinação; o contato do primeiro e do segundo sítios de ligação de recombinação com uma polipeptídeo de recombinase polipeptídeo de recombina-se, resultando na recombinação entre os sítios de ligação de recombinação, em que a polipeptídeo de recombinase pode mediar a recombinação entre o primeiro e o segundo sítios de ligação de recombinação, o primeiro sítio de ligação de recombinação é um sítio de ligação de recombinação genómico de fago (attP) ou um sítio de ligação de recombinação genómico bacteriano (attB), o segundo sítio é attB ou attP e a recombinase é selecionada do grupo consistindo em recombinase do fago da Listeria monocytogenes, uma recombinase do fago de Streptococcus pyo genes, uma recombinase do fago de Bacillus subtílis, uma recombinase do fago de Mycobacterium tuberculosis e uma recombinase do fago de Mycobacterium smegmatis, com a condição de que quando o primeiro sítio de ligação de recombinação é attB, o segundo sítio de ligação de recombinação é attP, e quando o primeiro sítio de ligação de recombinação é attP, o segundo sítio de ligação de recombinação é attB. A invenção também descreve composições, vetores e métodos da presente invenção que são também úteis em aplicações de terapia de genes.
BRPI0519865-8A 2005-02-02 2005-02-08 serina recombinases sìtio-especìficas e métodos para seu uso BRPI0519865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/049,552 US9034650B2 (en) 2005-02-02 2005-02-02 Site-specific serine recombinases and methods of their use
PCT/US2005/003851 WO2006083253A1 (en) 2005-02-02 2005-02-08 Site-specific serine recombinases and methods of their use

Publications (1)

Publication Number Publication Date
BRPI0519865A2 true BRPI0519865A2 (pt) 2009-03-24

Family

ID=36757054

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519865-8A BRPI0519865A2 (pt) 2005-02-02 2005-02-08 serina recombinases sìtio-especìficas e métodos para seu uso

Country Status (15)

Country Link
US (5) US9034650B2 (pt)
EP (3) EP2327786B1 (pt)
JP (4) JP5684445B2 (pt)
KR (1) KR20080003780A (pt)
CN (2) CN101194018B (pt)
AU (1) AU2005326917B2 (pt)
BR (1) BRPI0519865A2 (pt)
CA (4) CA3048118A1 (pt)
DK (2) DK2327786T3 (pt)
ES (2) ES2422424T3 (pt)
IL (3) IL185027A (pt)
MX (1) MX2007009349A (pt)
NZ (2) NZ556716A (pt)
SG (1) SG10201509276YA (pt)
WO (1) WO2006083253A1 (pt)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
EP1534738B1 (en) 2001-02-20 2012-06-20 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2424812T3 (es) 2001-02-20 2013-10-08 Intrexon Corporation Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso
EP1373470B1 (en) 2001-02-20 2013-04-24 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
AU2002247184B2 (en) 2001-02-20 2008-06-19 Intrexon Corporation Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
US7563879B2 (en) 2001-09-26 2009-07-21 Intrexon Corporation Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US8304233B2 (en) * 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
WO2006012031A1 (en) 2004-06-29 2006-02-02 Donaldson Company, Inc. Liquid filter arrangement and methods
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
US8906360B2 (en) 2005-07-22 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9238150B2 (en) * 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) * 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
JP2009538144A (ja) * 2006-05-22 2009-11-05 ハイプロセル・リミテッド・ライアビリティ・カンパニー 真核細胞株を用いたタンパク質産生
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
CA2685592C (en) 2007-05-02 2018-08-07 Intrexon Corporation Pp1 ligands
AU2008289461A1 (en) 2007-08-23 2009-02-26 Intrexon Corporation Methods and compositions for diagnosing disease
EP3156414B1 (en) 2007-09-26 2019-12-04 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
RU2484132C2 (ru) 2007-10-08 2013-06-10 Интрексон Корпорейшн Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей
US10035027B2 (en) * 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
MY169771A (en) 2008-04-23 2019-05-15 Univ Leland Stanford Junior Systems, methods and compositions for optical stimulation of target cells
AU2009256457B2 (en) 2008-05-29 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
CA2728238C (en) * 2008-06-17 2019-03-12 M. Bret Schneider Methods, systems and devices for optical stimulation of target cells using an optical transmission element
BRPI0915583A2 (pt) * 2008-06-17 2016-01-26 Univ Leland Stanford Junior aparelho e métodos para controle do desenvolvimento celular
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
US20110223635A1 (en) * 2008-08-11 2011-09-15 Karl Deisseroth Method and Composition for Controlling Gene Expression
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
CA2791094A1 (en) 2010-03-17 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
US20130195800A1 (en) 2010-03-23 2013-08-01 Intrexon Corporation Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
CN103491770B (zh) 2010-11-05 2016-06-08 斯坦福大学托管董事会 稳定阶跃函数视蛋白及其使用方法
EP3225108A1 (en) 2010-11-05 2017-10-04 The Board of Trustees of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
CN106376525A (zh) 2010-11-05 2017-02-08 斯坦福大学托管董事会 记忆功能的控制和表征
CA2816971A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
EP2635341B1 (en) 2010-11-05 2018-08-08 The Board of Trustees of the Leland Stanford Junior University Upconversion of light for use in optogenetic methods
WO2012061690A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US20120141441A1 (en) * 2010-12-03 2012-06-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Treatment of Muscular Dystrophy
US9402919B2 (en) 2011-03-04 2016-08-02 Intrexon Corporation Vectors conditionally expressing protein
EP3524676A1 (en) 2011-12-16 2019-08-14 The Board of Trustees of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
EP2817068B1 (en) 2012-02-21 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
CA2906756A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
CN105283439B (zh) 2013-03-15 2018-02-02 英特瑞克斯顿股份有限公司 含硼的二酰基肼类化合物
JP6549559B2 (ja) 2013-04-29 2019-07-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
CN105829538A (zh) 2013-08-14 2016-08-03 小利兰·斯坦福大学托管委员会 用于控制疼痛的组合物和方法
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
US9683280B2 (en) 2014-01-10 2017-06-20 Ut-Battelle, Llc Intermediate strength alloys for high temperature service in liquid-salt cooled energy systems
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US20170204399A1 (en) * 2014-08-15 2017-07-20 Massachusetts Institute Of Technology Genomically-encoded memory in live cells
WO2016044390A1 (en) 2014-09-17 2016-03-24 Intrexon Corporation Boron-containing diacylhydrazine compounds
MA41644A (fr) * 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
CN108884456A (zh) * 2015-10-01 2018-11-23 麻省理工学院 生物状态机
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
SG11201803934YA (en) 2015-11-11 2018-06-28 Intrexon Corp Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CA3049652A1 (en) * 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
AU2018281316B2 (en) 2017-06-07 2024-05-30 Precigen, Inc. Expression of novel cell tags
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN111712566A (zh) * 2018-02-08 2020-09-25 应用干细胞有限公司 用于筛选靶基因变体的方法
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
CN111019873B (zh) * 2018-10-09 2022-08-19 安徽吐露港生物科技有限公司 在食气梭菌基因组上快速整合大片段dna的方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN113614227A (zh) * 2018-11-02 2021-11-05 格林维纳斯有限责任公司 介导植物基因组稳定整合的丝氨酸重组酶
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN110093354B (zh) * 2019-04-17 2020-06-05 湖南杂交水稻研究中心 一种固定植物杂种优势的种子分选方法
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CA3148079A1 (en) * 2019-07-23 2021-01-28 Janssen Biotech, Inc. Synthetic genetic elements for biomanufacture of adeno-associated viruses
CA3157472A1 (en) * 2019-10-09 2021-04-15 The Jackson Laboratory High frequency targeted animal transgenesis
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021102390A1 (en) * 2019-11-22 2021-05-27 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
WO2021158651A1 (en) * 2020-02-04 2021-08-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling production of polypeptides in cells
CN113355345B (zh) * 2020-03-06 2023-05-23 深圳蓝晶生物科技有限公司 一种基因组整合外源序列的方法
EP4133086A4 (en) * 2020-04-07 2024-06-05 IO Biosciences, Inc. NUCLEIC ACID CONSTRUCTS WITH GENE-EDITING MULTI-SITES
BR112022022603A2 (pt) * 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
CN112458059B (zh) * 2020-11-25 2021-07-23 杭州景杰生物科技股份有限公司 一种识别H3 K18la兔单克隆抗体稳转细胞株及其构建方法
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US20260055430A1 (en) * 2021-03-08 2026-02-26 Flagship Pioneering Innovations Vi, Llc Lentivirus with altered integrase activity
WO2023064871A1 (en) 2021-10-14 2023-04-20 Asimov Inc. Integrases, landing pad architectures, and engineered cells comprising the same
CN114107380B (zh) * 2021-11-05 2024-06-07 上海药明生物技术有限公司 一种CHO-S.attp重组细胞株及其构建方法和应用
CA3265648A1 (en) * 2022-09-16 2024-03-21 Editas Medicine, Inc. NEW RECOMBINASES AND METHODS OF USE
WO2024102666A2 (en) * 2022-11-07 2024-05-16 Metagenomi, Inc. Serine recombinases for gene editing
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
EP4731757A2 (en) 2023-06-26 2026-04-29 University of Hawaii Evolved integrases and methods of using the same for genome editing
CN117089574A (zh) * 2023-08-25 2023-11-21 上海科技大学 一种构建用于外源基因定点整合的果蝇品系的方法
WO2025049788A1 (en) 2023-08-29 2025-03-06 The Broad Institute, Inc. Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish
WO2025096916A1 (en) 2023-11-03 2025-05-08 The Broad Institute, Inc. Multi-site editing in living cells
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025259766A1 (en) * 2024-06-11 2025-12-18 Komo Biosciences, Inc. Genome editing using evolved integrases
CN119286893A (zh) * 2024-12-11 2025-01-10 三亚中国农业科学院国家南繁研究院 一种重组酶位点变体的筛选方法
CN119307470A (zh) * 2024-12-13 2025-01-14 三亚中国农业科学院国家南繁研究院 一种丝氨酸重组酶及其在植物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69012601T2 (de) * 1989-02-02 1995-01-19 Joel S Greenberger Gentherapie durch stützgewebebezügliche Zellen.
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5763198A (en) 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5919653A (en) * 1996-08-20 1999-07-06 Allelix Neuroscience Inc. Nucleic acids encoding a human glycine transporter
US6114600A (en) * 1997-10-31 2000-09-05 The United States Of America As Represented By The Secretary Of Agriculture Resolution of complex integration patterns to obtain single copy transgenes
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
US6746870B1 (en) * 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
ATE490338T1 (de) * 2000-02-18 2010-12-15 Univ Leland Stanford Junior Veränderte rekombinasen zur modifizierung des genoms
CN1455817A (zh) * 2000-07-21 2003-11-12 (由农业部部长代表的)美利坚合众国 用于在真核基因组中置换、转移和富积dna的方法
ATE303403T1 (de) 2000-11-10 2005-09-15 Artemis Pharmaceuticals Gmbh Modifizierte rekombinase
JP4068297B2 (ja) 2000-11-21 2008-03-26 独立行政法人科学技術振興機構 Ｙ型六方晶系フェライト薄膜およびその製造方法
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US8304233B2 (en) * 2002-06-04 2012-11-06 Poetic Genetics, Llc Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
WO2005017170A2 (en) * 2002-06-04 2005-02-24 Michele Calos Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same
WO2004020605A2 (en) * 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US7491539B2 (en) * 2002-12-05 2009-02-17 Boehringer Ingelheim Pharma Kg Sequence specific DNA recombination in eukaryotic cells
WO2004080162A2 (en) 2003-03-07 2004-09-23 Avigenics, Inc. Integrase mediated avian transgenesis
US20050034186A1 (en) 2003-03-07 2005-02-10 Harvey Alex J. Site specific nucleic acid integration
US20060046294A1 (en) * 2004-08-26 2006-03-02 The United States Of America, As Represented By The Secretary Of Agriculture Site-specific recombination systems for use in eukaryotic cells
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection

Also Published As

Publication number Publication date
JP2017136080A (ja) 2017-08-10
JP6158639B2 (ja) 2017-07-05
WO2006083253A1 (en) 2006-08-10
SG10201509276YA (en) 2015-12-30
CN102994492A (zh) 2013-03-27
NZ583562A (en) 2012-04-27
DK2327786T3 (en) 2016-08-15
CA2595929C (en) 2016-02-02
EP1844155B1 (en) 2013-04-24
CA2914181C (en) 2019-08-06
IL211819A (en) 2015-01-29
EP1844155A1 (en) 2007-10-17
US20170114370A1 (en) 2017-04-27
US10081817B2 (en) 2018-09-25
EP2327786A3 (en) 2012-03-21
DK1844155T3 (da) 2013-07-29
CA2595929A1 (en) 2006-08-10
CN101194018A (zh) 2008-06-04
US20080020465A1 (en) 2008-01-24
US20060172377A1 (en) 2006-08-03
HK1107119A1 (en) 2008-03-28
IL185027A0 (en) 2007-12-03
JP5684445B2 (ja) 2015-03-11
ES2422424T3 (es) 2013-09-11
JP2011167195A (ja) 2011-09-01
CA3048118A1 (en) 2006-08-10
EP2327786B1 (en) 2016-04-27
JP2014000085A (ja) 2014-01-09
EP1844155A4 (en) 2008-03-12
MX2007009349A (es) 2008-03-07
JP2008528056A (ja) 2008-07-31
CA2827515A1 (en) 2006-08-10
AU2005326917B2 (en) 2012-04-19
AU2005326917A1 (en) 2006-08-10
US20150275232A1 (en) 2015-10-01
ES2584911T3 (es) 2016-09-30
IL211819A0 (en) 2011-05-31
KR20080003780A (ko) 2008-01-08
IL211820A (en) 2015-01-29
EP2327786A2 (en) 2011-06-01
JP5796975B2 (ja) 2015-10-21
JP6577969B2 (ja) 2019-09-18
IL185027A (en) 2014-04-30
EP3112457A1 (en) 2017-01-04
NZ556716A (en) 2011-02-25
US10648003B2 (en) 2020-05-12
CN102994492B (zh) 2015-04-29
US9034650B2 (en) 2015-05-19
IL211820A0 (en) 2011-05-31
CA2914181A1 (en) 2006-08-10
CN101194018B (zh) 2012-11-28
US20180346934A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
EP2327786A3 (en) Site-specific serine recombinases and methods of their use
Smith Phage‐encoded serine integrases and other large serine recombinases
Huang et al. A rapid seamless method for gene knockout in Pseudomonas aeruginosa
ES2626411T3 (es) Producción de ácido nucleico circular monocatenario
Hatfull Mycobacteriophages: genes and genomes
Daccord et al. Comparative analysis of mobilizable genomic islands
BR112023003784A2 (pt) Sistema crispr-cas (casmini) em miniatura sintético para engenharia de genoma eucariótico
Grüll et al. Small extracellular particles with big potential for horizontal gene transfer: membrane vesicles and gene transfer agents
Huo et al. Genome modification in Enterococcus faecalis OG1RF assessed by bisulfite sequencing and single-molecule real-time sequencing
WO2015160895A3 (en) Modified transposases for improved insertion sequence bias and increased dna input tolerance
PT1032680E (pt) Um novo metodo para a integracao de adn estranho em genomas eucarioticos
WO2003087301A3 (en) Methods and compositions for dna manipulation
WO2010093966A3 (en) A dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion
Fogg et al. Genome integration and excision by a new Streptomyces bacteriophage, ϕJoe
US20200354770A1 (en) Cation chelator hot start
Kiljunen et al. Generation of comprehensive transposon insertion mutant library for the model archaeon, Haloferax volcanii, and its use for gene discovery
ES2150755T3 (es) Copolimeros injertados, su procedimiento de preparacion, las composiciones que los contienen y su utilizacion para la preparacion de dispersiones pigmentarias en medio acuoso y/o organico.
BR112022008861A2 (pt) Construto de ácido nucleico, vetor, nanopartícula lipídica, célula, composição para uso na expressão de retinosquisina, método para integrar uma sequência de codificação, e, método para modificar um gene rs1
Lyras et al. The large resolvase TnpX is the only transposon‐encoded protein required for transposition of the Tn4451/3 family of integrative mobilizable elements
Cossu et al. Flipping chromosomes in deep-sea archaea
Madhusoodanan et al. Diversity of DNA methyltransferases that recognize asymmetric target sequences
WO2023114473A3 (en) Recombinant reverse transcriptase variants for improved performance
Tribble et al. Transposition genes of the Bacteroides mobilizable transposon Tn4555: role of a novel targeting gene
WO2020165901A8 (en) Site specific recombinase integrase variants and uses thereof in gene editing in eukaryotic cells
DE602007010921D1 (de) Pseudotransposons und rekombinante hyperaktive transpositionssysteme, abgeleitet vom mos-1-transposon

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]